

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT4921718

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
BO YU	10/03/2015
RIJIAN WANG	11/11/2015
KEITH REIMANN	11/11/2015
RECEIVING PARTY DATA	
Name:	PRIMATOPE THERAPEUTICS INC.
Street Address:	508 DUDLEY ROAD
City:	NEWTON
State/Country:	MASSACHUSETTS
Postal Code:	02459
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15955393
CORRESPONDENCE DATA	
Fax Number:	(914)288-0023
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	9142880022
Email:	uspto@leasonellis.com
Correspondent Name:	LEASON ELLIS LLP
Address Line 1:	ONE BARKER AVENUE
Address Line 2:	FIFTH FLOOR
Address Line 4:	WHITE PLAINS, NEW YORK 10601-1526
ATTORNEY DOCKET NUMBER:	11212/005211-US2
NAME OF SUBMITTER:	MICHAEL A. DAVITZ
SIGNATURE:	/MICHAEL A. DAVITZ/
DATE SIGNED:	04/18/2018
Total Attachments: 2	
source=01929700#page1.tif	
source=01929700#page2.tif	

ASSIGNMENT

WHEREAS, We, **Bo Yu, Rijian Wang, and Keith Reimann**, have invented certain new and useful improvements in **HUMANIZED ANTI-CD40 ANTIBODIES AND USES THEREOF** for which a provisional application for patent in the United States was filed as U.S. Serial No. 62/214,411 on September 4, 2015 (the "Application");

AND WHEREAS, **PRIMATOPE THERAPEUTICS INC.**, with its principal place of business at 508 Dudley Rd, Newton, MA 02459, US, is entitled to acquire the entire right, title and interest in and to the invention and the application.

NOW, THEREFORE, for good and valuable consideration, including salary or payment for the making the invention or employee benefit, the receipt of which we acknowledge here, we agree to sell, assign and transfer and do hereby sell, assign and transfer to **PRIMATOPE THERAPEUTICS INC.**, its successors, legal representatives and assigns, the entire right, title and interest throughout the world in and to the invention, the Application (including the right to claim priority therefrom), any United States patent which may be granted from a U.S. nonprovisional application claiming priority to the Application or any division, continuation or continuation-in-part thereof, or any reissue or extension of such United States patent, and all rights of priority under International Conventions and applications for patent which may be filed for the invention in any country or state foreign to the United States, and any patent which may be granted for the invention in any country or state foreign to the United States and any extension, renewal and reissue from the patent; and we hereby authorize and request the Commissioner of Patents of the United States, and any Official of any country foreign to the United States, whose duty it is to issue patents on applications as aforesaid, to issue any patent for the invention to **PRIMATOPE THERAPEUTICS INC.**, its successors, legal representatives and assigns, in accordance with the terms of this instrument.


AND we hereby agree that we will communicate to **PRIMATOPE THERAPEUTICS INC.**, its successors, legal representatives, and assigns, any fact known to us respecting the invention and testify in any legal proceeding, sign lawful papers, execute any divisional, continuing, and reissue application, make all rightful oaths and generally do everything possible to aid **PRIMATOPE THERAPEUTICS INC.**, its successors, legal representatives, and assigns, to obtain and enforce proper patent protection for the invention in any country.

IN TESTIMONY WHEREOF, I hereunto set my hand and seal this 3 day of Oct, 2015.



Bo Yu


Witnessed by:

IN TESTIMONY WHEREOF, I hereunto set my hand and seal this 11 day
of November, 2015




Rujian Wang




Witnessed by:
Chad Tu, PhD.

IN TESTIMONY WHEREOF, I hereunto set my hand and seal this 11th day
of November, 2015.




Keith Reimann




Witnessed by: Aaron T. Bell

Accepted by PRIMATOPE THERAPEUTICS INC.:



(Print Name)



(Signature)

President & CEO

Title Capacity

11/11/15

Date